Ambrosetti A, Nadali G, Vinante F, Ricetti M M, Todeschini G, Morosato L, de Sabata D, Bergamo Andreis I A, Chilosi M, Semenzato G
Department of Hematology, Verona University School of Medicine, Italy.
Int J Clin Lab Res. 1993;23(1):34-7. doi: 10.1007/BF02592278.
The CD25 molecule, which corresponds to the p55 alpha chain of the interleukin-2 receptor, is strongly expressed by neoplastic cells in hairy-cell leukemia and is released in large amounts in the soluble form which is detectable in serum. In order to assess the reliability of the soluble interleukin-2 receptor as a disease marker in the management of patients with hairy-cell leukemia, we investigated serum levels in 35 untreated patients and in 2 patients with the hairy-cell leukemia variant. In 21 of 35 patients soluble receptor levels were also monitored during and after recombinant interferon-alpha therapy. Clinical and hematological parameters were also assessed. Soluble interleukin-2 receptor levels were extremely high at the time of diagnosis in patients with typical hairy-cell leukemia [32,722 +/- 27,001 vs. 331 +/- 145 units/ml in controls (mean +/- SD)], but not in patients with the leukemia variant. A progressive decrease in soluble interleukin-2 receptor levels paralleled the clinical response to treatment, although normal values were never detected, even in patients who achieved an apparent complete remission. After recombinant interferon-alpha discontinuation, disease recurrence was accompanied by a progressive increase to pre-treatment soluble receptor levels. Overall, a close correlation was found between soluble interleukin-2 receptor values and total tumor burden (r = 0.84, P < 0.001). On the basis of these data, soluble interleukin-2 receptor should be regarded as a key marker in the management of patients with hairy-cell leukemia.
CD25分子，相当于白细胞介素-2受体的p55α链，在毛细胞白血病的肿瘤细胞中强烈表达，并以可溶形式大量释放，可在血清中检测到。为了评估可溶性白细胞介素-2受体作为毛细胞白血病患者管理中疾病标志物的可靠性，我们调查了35例未经治疗的患者和2例毛细胞白血病变异型患者的血清水平。在35例患者中的21例，在重组干扰素-α治疗期间及之后也监测了可溶性受体水平。还评估了临床和血液学参数。典型毛细胞白血病患者诊断时可溶性白细胞介素-2受体水平极高[32,722±27,001 vs. 对照组331±145单位/毫升（均值±标准差）]，但白血病变异型患者并非如此。可溶性白细胞介素-2受体水平的逐渐下降与治疗的临床反应平行，尽管即使在达到明显完全缓解的患者中也从未检测到正常值。重组干扰素-α停药后，疾病复发伴随着可溶性受体水平逐渐升高至治疗前水平。总体而言，可溶性白细胞介素-2受体值与总肿瘤负荷之间存在密切相关性（r = 0.84，P < 0.001）。基于这些数据，可溶性白细胞介素-2受体应被视为毛细胞白血病患者管理中的关键标志物。
